0.7995
price up icon10.44%   0.0756
 
loading
前日終値:
$0.7239
開ける:
$0.7127
24時間の取引高:
7.01M
Relative Volume:
1.61
時価総額:
$211.39M
収益:
-
当期純損益:
$-63.08M
株価収益率:
-2.9611
EPS:
-0.27
ネットキャッシュフロー:
$-72.53M
1週間 パフォーマンス:
+32.24%
1か月 パフォーマンス:
+31.02%
6か月 パフォーマンス:
-21.62%
1年 パフォーマンス:
-51.25%
1日の値動き範囲:
Value
$0.7002
$0.80
1週間の範囲:
Value
$0.61
$0.80
52週間の値動き範囲:
Value
$0.515
$2.08

Ocugen Inc Stock (OCGN) Company Profile

Name
名前
Ocugen Inc
Name
セクター
Healthcare (1166)
Name
電話
484-328-4701
Name
住所
11 GREAT VALLEY PARKWAY, MALVERN, PA
Name
職員
0
Name
Twitter
@Ocugen
Name
次回の収益日
2025-03-05
Name
最新のSEC提出書
Name
OCGN's Discussions on Twitter

OCGN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
OCGN
Ocugen Inc
0.7995 211.39M 0 -63.08M -72.53M -0.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Ocugen Inc Stock (OCGN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-10-15 開始されました Maxim Group Buy
2023-03-01 アップグレード Chardan Capital Markets Neutral → Buy
2022-08-23 開始されました Mizuho Buy
2022-06-15 再開されました ROTH Capital Buy
2022-06-02 開始されました Cantor Fitzgerald Overweight
2021-07-26 開始されました Noble Capital Markets Outperform
2021-06-11 ダウングレード ROTH Capital Buy → Neutral
2021-05-07 ダウングレード Cantor Fitzgerald Overweight → Neutral
2021-02-09 ダウングレード Chardan Capital Markets Buy → Neutral
2021-02-04 アップグレード H.C. Wainwright Neutral → Buy
すべてを表示

Ocugen Inc (OCGN) 最新ニュース

pulisher
Mar 22, 2025

Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results - MSN

Mar 22, 2025
pulisher
Mar 20, 2025

Stock Quote & Chart - Ocugen

Mar 20, 2025
pulisher
Mar 19, 2025

Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200 - Yahoo

Mar 19, 2025
pulisher
Mar 19, 2025

Ocugen’s OCU200 advances to next trial phase with safety approval By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

ROSEN, A LEADING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important August 17 Deadline in Securities Class Action – OCGN - Business Wire

Mar 19, 2025
pulisher
Mar 18, 2025

OCGN stock touches 52-week low at $0.52 amid market challenges By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

OCGN stock touches 52-week low at $0.52 amid market challenges - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Ocugen Advances OCU200 Trial After Safety Board Review -March 18, 2025 at 08:31 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Ocugen says DSMB approves dosing Cohort 2 in OCU200 clinical trial - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Ocugen’s OCU200 advances to next trial phase with safety approval - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Ocugen Announces Approval to Continue Dosing in Phase 1 Trial of OCU200 Following Favorable Safety Review - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema - Ocugen

Mar 18, 2025
pulisher
Mar 18, 2025

Data and Safety Monitoring Board Reviews Cohort 1 Safety - GlobeNewswire

Mar 18, 2025
pulisher
Mar 17, 2025

Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial - MSN

Mar 17, 2025
pulisher
Mar 12, 2025

Ocugen Inc. Navigates Uncertainty Amid Potential Shifts in U.S. Fiscal and Tax Policies - MSN

Mar 12, 2025
pulisher
Mar 12, 2025

SBI Securities Co. Ltd. Makes New $40,000 Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World

Mar 12, 2025
pulisher
Mar 10, 2025

Ocugen, Inc. (NASDAQ:OCGN) Shares Acquired by Rhumbline Advisers - Defense World

Mar 10, 2025
pulisher
Mar 10, 2025

Equities Analysts Offer Predictions for Ocugen Q1 Earnings - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

FY2029 Earnings Estimate for Ocugen Issued By HC Wainwright - Defense World

Mar 09, 2025
pulisher
Mar 09, 2025

Ocugen’s (OCGN) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Ocugen Secures ATMP Classification for Gene Therapies Targeting Vision Loss - MSN

Mar 08, 2025
pulisher
Mar 07, 2025

Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates - MSN

Mar 07, 2025
pulisher
Mar 07, 2025

Ocugen’s Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Ocugen Reports 2024 Financial Results and Advances Gene Therapy Programs - MSN

Mar 07, 2025
pulisher
Mar 06, 2025

Attention Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.

Mar 06, 2025
pulisher
Mar 06, 2025

Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating -March 06, 2025 at 08:15 am EST - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Ocugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 06, 2025
pulisher
Mar 06, 2025

Ocugen’s Strategic BLA Submissions and Financial Position Support Buy Rating - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Beyond The Numbers: 5 Analysts Discuss Ocugen Stock - Benzinga

Mar 06, 2025
pulisher
Mar 06, 2025

Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Ocugen: Q4 Earnings Snapshot - Midland Daily News

Mar 06, 2025
pulisher
Mar 06, 2025

Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance

Mar 06, 2025
pulisher
Mar 05, 2025

Ocugen Reports Progress in Gene Therapy Trials - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

Ocugen Inc Earnings Call: Strategic Gains Amid Financial Challenges - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025 - CGTLive™

Mar 05, 2025
pulisher
Mar 05, 2025

Ocugen Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 05, 2025
pulisher
Mar 05, 2025

Ocugen (OCGN) Q4 2024 Earnings Call Transcript - Yahoo

Mar 05, 2025
pulisher
Mar 05, 2025

Ocugen’s Geographic Atrophy and Stargardt Gene Therapies Garner Positive ATMP Opinions from EMA - CGTLive™

Mar 05, 2025
pulisher
Mar 05, 2025

Earnings call transcript: Ocugen Q4 2024 beats earnings forecast By Investing.com - Investing.com UK

Mar 05, 2025
pulisher
Mar 05, 2025

Ocugen to Announce Q4 and Full-Year 2024 Results with Live Webcast on March 5, 2025 - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Ocugen, Inc. SEC 10-K Report - TradingView

Mar 05, 2025
pulisher
Mar 05, 2025

Earnings call transcript: Ocugen Q4 2024 beats earnings forecast - Investing.com

Mar 05, 2025
pulisher
Mar 05, 2025

Ocugen Inc (OCGN) Q4 Earnings: Revenue Surpasses Estimates at $0 - GuruFocus.com

Mar 05, 2025

Ocugen Inc (OCGN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Ocugen Inc (OCGN) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Castillo Kirsten
Director
Nov 22 '24
Buy
0.91
25,000
22,848
75,000
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):